{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:55Z","timestamp":1787008975152,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH119149"],"award-info":[{"award-number":["R01MH119149"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fragile X syndrome (FXS) is caused by mutations in the FMR1 gene. It is a form of heritable intellectual disability and autism. Despite recent advance in elucidating disease mechanisms, there is no efficacious medication. Because de novo drug development is a lengthy process, repurposing the existing FDA-approved drugs offers an opportunity to advance clinical intervention for FXS. Our previous study with transcriptome analysis predicts potential therapeutic effects of vorinostat on FXS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the vorinostat-induced transcriptome changes and confirmed its similarity to that induced by trifluoperazine, which was previously shown to correct pathological outcomes associated with FXS. To validate the therapeutic efficacy, we examined vorinostat\u2019s effect on correcting the key behavioral and cellular symptoms in a mouse model of FXS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that vorinostat restores object location memory and passive avoidance memory in the Fmr1 knockout mice. For the non-cognitive behavioral symptoms, vorinostat corrected the autism-associated alterations, including repetitive behavior and social interaction deficits. In the open field test, vorinostat dampened hyperactivity in the center area of the arena. Surprisingly, vorinostat did not correct the abnormally elevated protein synthesis in cultured Fmr1 knockout hippocampal neurons, suggesting that different aspects of pathological outcomes may respond differently to a specific therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We used the drug-induced transcriptome signature to predict new application of existing drugs. Our data reveal the therapeutic effects of the FDA-approved drug vorinostat in a mouse model of FXS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyab081","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T15:11:21Z","timestamp":1636729881000},"page":"147-159","source":"Crossref","is-referenced-by-count":10,"title":["Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome"],"prefix":"10.1093","volume":"25","author":[{"given":"Qi","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Physiology Michigan State University, East Lansing, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Physiology Michigan State University, East Lansing, Michigan, USA"},{"name":"Neuroscience Program Michigan State University, East Lansing, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2022021109235988400_CIT0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2022021109235988400_CIT0002","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1038\/s41598-019-41744-7","article-title":"Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex","volume":"9","author":"Basu","year":"2019","journal-title":"Sci Rep"},{"key":"2022021109235988400_CIT0003","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1172\/JCI79942","article-title":"HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models","volume":"125","author":"Benito","year":"2015","journal-title":"J Clin Invest"},{"key":"2022021109235988400_CIT0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2022021109235988400_CIT0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","article-title":"Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice","volume":"76","author":"Bhattacharya","year":"2012","journal-title":"Neuron"},{"key":"2022021109235988400_CIT0006","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/npp.2015.369","article-title":"Targeting translation control with p70 S6 kinase 1 inhibitors to reverse phenotypes in fragile X syndrome mice","volume":"41","author":"Bhattacharya","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"2022021109235988400_CIT0007","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem Soc Rev"},{"key":"2022021109235988400_CIT0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0092-8674(01)00568-2","article-title":"Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome","volume":"107","author":"Brown","year":"2001","journal-title":"Cell"},{"key":"2022021109235988400_CIT0009","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/nn.3379","article-title":"The translation of translational control by FMRP: therapeutic targets for FXS","volume":"16","author":"Darnell","year":"2013","journal-title":"Nat Neurosci"},{"key":"2022021109235988400_CIT0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","article-title":"FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism","volume":"146","author":"Darnell","year":"2011","journal-title":"Cell"},{"key":"2022021109235988400_CIT0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbr.2014.05.046","article-title":"Behavioral analysis of male and female Fmr1 knockout mice on C57BL\/6 background","volume":"271","author":"Ding","year":"2014","journal-title":"Behav Brain Res"},{"key":"2022021109235988400_CIT0012","doi-asserted-by":"crossref","first-page":"9327","DOI":"10.3390\/ijms21239327","article-title":"Carbamazepine restores neuronal signaling, protein synthesis, and cognitive function in a mouse model of fragile X syndrome","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2022021109235988400_CIT0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s42003-020-0833-4","article-title":"Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model","volume":"3","author":"Ding","year":"2020","journal-title":"Communications biology"},{"key":"2022021109235988400_CIT0014","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","article-title":"Correction of fragile X syndrome in mice","volume":"56","author":"D\u00f6len","year":"2007","journal-title":"Neuron"},{"key":"2022021109235988400_CIT0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pharmthera.2010.02.008","article-title":"Mechanism-based approaches to treating fragile X","volume":"127","author":"D\u00f6len","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2022021109235988400_CIT0016","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cge.13039","article-title":"Metformin as targeted treatment in fragile X syndrome","volume":"93","author":"Dy","year":"2018","journal-title":"Clin Genet"},{"key":"2022021109235988400_CIT0017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2022021109235988400_CIT0018","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1126\/science.aad6469","article-title":"Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap","volume":"359","author":"Gandal","year":"2018","journal-title":"Science"},{"key":"2022021109235988400_CIT0019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","article-title":"Affy\u2013analysis of Affymetrix GeneChip data at the probe level","volume":"20","author":"Gautier","year":"2004","journal-title":"Bioinformatics"},{"key":"2022021109235988400_CIT0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.celrep.2015.03.065","article-title":"Selective role of the catalytic PI3K subunit p110\u03b2 in impaired higher order cognition in fragile X syndrome","volume":"11","author":"Gross","year":"2015","journal-title":"Cell Rep"},{"key":"2022021109235988400_CIT0021","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41386-018-0150-5","article-title":"Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model","volume":"44","author":"Gross","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2022021109235988400_CIT0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature07925","article-title":"HDAC2 negatively regulates memory formation and synaptic plasticity","volume":"459","author":"Guan","year":"2009","journal-title":"Nature"},{"key":"2022021109235988400_CIT0023","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022021109235988400_CIT0024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"2022021109235988400_CIT0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/msb.2013.20","article-title":"Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding","volume":"9","author":"Iskar","year":"2013","journal-title":"Mol Syst Biol"},{"key":"2022021109235988400_CIT0026","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/ddy099","article-title":"Protein synthesis levels are increased in a subset of individuals with fragile X syndrome","volume":"27","author":"Jacquemont","year":"2018","journal-title":"Human Mol Gen"},{"key":"2022021109235988400_CIT0027","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.neuron.2004.06.002","article-title":"CBP histone acetyltransferase activity is a critical component of memory consolidation","volume":"42","author":"Korzus","year":"2004","journal-title":"Neuron"},{"key":"2022021109235988400_CIT0028","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"2022021109235988400_CIT0029","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1038\/s41467-018-04869-3","article-title":"Reducing histone acetylation rescues cognitive deficits in a mouse model of fragile X syndrome","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"2022021109235988400_CIT0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"2022021109235988400_CIT0031","doi-asserted-by":"crossref","first-page":"15616","DOI":"10.1523\/JNEUROSCI.3888-10.2010","article-title":"Hypersensitivity to mGluR5 and ERK1\/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome","volume":"30","author":"Osterweil","year":"2010","journal-title":"J Neurosci"},{"key":"2022021109235988400_CIT0032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","article-title":"Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome","volume":"77","author":"Osterweil","year":"2013","journal-title":"Neuron"},{"key":"2022021109235988400_CIT0033","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1469-1809.2011.00694.x","article-title":"Fragile X syndrome: the FMR1 CGG repeat distribution among world populations","volume":"76","author":"Peprah","year":"2012","journal-title":"Ann Hum Genet"},{"key":"2022021109235988400_CIT0034","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","article-title":"Applications of Connectivity Map in drug discovery and development","volume":"17","author":"Qu","year":"2012","journal-title":"Drug Discov Today"},{"key":"2022021109235988400_CIT0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-011811-132457","article-title":"Molecular mechanisms of fragile X syndrome: a twenty-year perspective","volume":"7","author":"Santoro","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"2022021109235988400_CIT0036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.1314","article-title":"SUnSET, a nonradioactive method to monitor protein synthesis","volume":"6","author":"Schmidt","year":"2009","journal-title":"Nat Methods"},{"key":"2022021109235988400_CIT0037","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11064-013-1229-3","article-title":"From FMRP function to potential therapies for fragile X syndrome","volume":"39","author":"Sethna","year":"2014","journal-title":"Neurochem Res"},{"key":"2022021109235988400_CIT0038","doi-asserted-by":"crossref","first-page":"14359","DOI":"10.1038\/ncomms14359","article-title":"Enhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model","volume":"8","author":"Sethna","year":"2017","journal-title":"Nat Commun"},{"key":"2022021109235988400_CIT0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12031-014-0461-x","article-title":"Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice","volume":"56","author":"Sharma","year":"2015","journal-title":"J Mol Neurosci"},{"key":"2022021109235988400_CIT0040","doi-asserted-by":"crossref","first-page":"124548","DOI":"10.1155\/2012\/124548","article-title":"Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome","volume":"2012","author":"Siller","year":"2012","journal-title":"Neural Plast"},{"key":"2022021109235988400_CIT0041","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nn.4618","article-title":"Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry","volume":"20","author":"So","year":"2017","journal-title":"Nat Neurosci"},{"key":"2022021109235988400_CIT0042","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nn.4216","article-title":"Adult mouse cortical cell taxonomy revealed by single cell transcriptomics","volume":"19","author":"Tasic","year":"2016","journal-title":"Nat Neurosci"},{"key":"2022021109235988400_CIT0043","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2018.05.004","article-title":"Repurposing available drugs for neurodevelopmental disorders: the fragile X experience","volume":"147","author":"Tranfaglia","year":"2019","journal-title":"Neuropharmacology"},{"key":"2022021109235988400_CIT0044","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","article-title":"Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP","volume":"49","author":"Yan","year":"2005","journal-title":"Neuropharmacology"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab081\/41661699\/pyab081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/2\/147\/42497321\/pyab081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/2\/147\/42497321\/pyab081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T04:24:44Z","timestamp":1644553484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/25\/2\/147\/6430443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,17]]},"published-print":{"date-parts":[[2022,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyab081","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.05.238568","asserted-by":"object"}]},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,11,17]]}}}